Pivotal bioVenture Partners Investment Advisor’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,375,000	Closed	-$13.8M	–	13
2023 Q4	$13.8M	Hold	1,375,000	–	–	3.5%	6
2023 Q3	$3.96M	Buy	+1,375,000	New	+$5.03M	1.58%	8

Pivotal bioVenture Partners Investment Advisor's GRCL Position: Q1 2024 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 1,375,000 shares — an estimated $13.8M sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in GRCL in Q3 2023 and held it in 2 quarters. The position peaked at $13.8M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Pivotal bioVenture Partners Investment Advisor reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Pivotal bioVenture Partners Investment Advisor sold 1,375,000 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $13.8M.
Pivotal bioVenture Partners Investment Advisor first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023 and held it in 2 quarters.
Pivotal bioVenture Partners Investment Advisor's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $13.8M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2024, filed 14 May 2024.